MorphoSys Proprietary Development Update

(1)

MorphoSys Proprietary

Development Update

September 8, 2015

1 © MorphoSys - Proprietary Development Update

(2)

Safe Harbor

This presentation includes forward-looking statements.

Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive

conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing. These and other risks and uncertainties are detailed in the Company’s Annual Report.

(3)

Today on the Call

Simon Moroney CEO Jens Holstein CFO Claudia Gutjahr-Löser Head of Corporate Communications & IR Arndt Schottelius CDO Marlies Sproll CSO 3

(4)

3rd _stage:

Co-development deals

Co-Development

Towards a Fully-integrated Biopharmaceutical

Company

C

omp

an

y

D

evelopm

ent

Time

Technology driven License Agreements Tech Transfer Funded Research 2nd _stage: Pure out-licensing Product driven Out-licensing 4th _stage: In-licensing

Product and target driven In-licensing Co-Discovery / Co-Development Innovation Capital M&A

5

_th

stage:

1st _stage: Technology commercialization Fully-integrated biopharmaceutical company

(5)

MOR208 – Significant Medical Need Exists

Significant medical need in treatment of Non-Hodgkin‘s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL):

 DLBCL: 26,000 new cases and 7,300 deaths in 2015 in the US1,2

 CLL: 14,620 new cases and 4,650 deaths in 2015 in the US1

 Anti-CD20 approaches (rituximab) improved the prognosis for many CLL/NHL patients

 Some patients can be cured but the majority of patients do not respond to therapy or relapse

 ~40% of DLBCL patients cannot be cured by chemoimmunotherapy and/or autologous stem cell transplantation and eventually relapse3

 CLL patients cannot be cured, chemoimmunotherapy leads to treatment-free intervals of more than 5 years but the majority of patients cannot tolerate this treatment4

1: Cancer.gov

2: Decision Resources

3: Mounier et al. Best Pract Res Clin Haematol. 2012 4: Hallek et al. Ann Oncol. 2010

Best in Class Potential in Several B cell Malignancies

OPPORTUNITY MOR208 addresses central gaps in current B cell cancer treatment options,

including CD20 down-regulation, TKI relapses, and treatment in patients unable to manage side effects of TKIs

(6)

MOR208 – Multiple Studies Commencing in Late

2015 and 2016

2015 2016 2017 2018* NHL DLBCL CLL ALL

Phase 2: MOR208 (12mg/kg) plus lenalidomide (N=80) Phase 2: MOR208 mono

(N=92)

Safety evaluation leading into anticipated pivotal study (12 mg/kg MOR208 plus bendamustine), N~320

Ph. 2 (ongoing OSU IIT): R/R & naive CLL & Richter’s Transformation, MOR208 (9mg/kg) plus LEN, N=50 Phase 2: MOR208 (12mg/kg) plus idelalisib, BTKi-failures, N=120

Phase 2 (St. Jude’s IIT): Pedriatic ALL, MOR208 (12mg/kg) plus NK cells, N=13

*no outlook given beyond 2018

NEXT STEPS  Phase 2 trial with LEN in 2nd line R/R DLBCL to start in Q4 2015

 Phase 2 trial with IDE in CLL in BTKi-failures to start in Q1 2016

 Phase 3 combo trial with BEN in 2nd _{line R/R DLBCL aimed to start in 2017}

 Update on NHL monotherapy planned at ASH 2015

Phase 3 Phase 2 IIT

(7)

2015 2016 2017 2018*

MM

MOR202 – Clinical Development Plan

STATUS  Phase 1/2a clinical trial in MM ongoing

 Cohorts with 16mg/kg weekly dosing + Dex and combination cohorts (MOR202 + LEN + Dex and MOR202 + POM + Dex) are ongoing

 Encouraging early signs of activity already at low doses

 Higher level of activity expected at further dose escalation allowing full target saturation

Phase 1/2a MOR202 (8 and 16mg/kg) plus lenalidomide or pomalidomide and confirmation cohorts (N~24)

Phase 1/2a MOR202 mono, dose escalation, plus confirmation cohorts (N~62)

Phase 3: MOR202 combination therapy

Phase 3 Phase 2

(8)

2015 2016 2017 2018*

mCRP

MOR209/ES414 – New Treatment Option in

mCRPC

STATUS  Preclinical studies successfully concluded, promising results presented in 2013

 Pharmacologically active and well tolerated

 Shows activity at very low doses

 Increased half-life due to bi-specific ADAPTIR-structure

 Phase 1 in mCRPC in the U.S. and Australia ongoing

 Stage 1: identify MTD of MOR209/ES414 administered iv

 Stage 2: evaluate clinical activity in patients that have or have not received prior chemotherapy

NEXT  First clinical data expected in 2016

MOR209/ES414: Phase 1/2 dose escalation (N~50)

MOR209/ES414: Phase 1/2 dose extension (N~80)

Phase 3 preparations

Phase 3 Phase 2

(9)

Leveraging Technology Leadership

Inflammation

Peptides

GPCR targets

Immuno-oncology

Galapagos  Co-development alliance  MOR106 to enter clinical development in 2016 in inflammation Lanthio  Stabilized peptide technology complements existing antibody drug discovery platform  MOR107 to enter clinical development in 2016 in fibrotic diseases Heptares/Sosei  Delivers challenging GPCRs in stabilized form as drug targets

G7 Therapeutics  Delivers tailor-made GPCRs as drug targets Merck Serono  Developing antibodies against immune checkpoints Immatics  Developing antibody-based therapies targeting tumor-associated peptides

(10)

Q&A Session